

Correction

Open Access

## Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-I integrase inhibitors

Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati\*

Address: Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, CA 90089, USA

Email: Erik Serrao - [eserrao@usc.edu](mailto:eserrao@usc.edu); Srinivas Odde - [odde@usc.edu](mailto:odde@usc.edu); Kavya Ramkumar - [ramkumar@usc.edu](mailto:ramkumar@usc.edu); Nouri Neamati\* - [neamati@usc.edu](mailto:neamati@usc.edu)

\* Corresponding author

Published: 8 April 2009

Received: 7 April 2009

*Retrovirology* 2009, **6**:33 doi:10.1186/1742-4690-6-33

Accepted: 8 April 2009

This article is available from: <http://www.retrovirology.com/content/6/1/33>

© 2009 Serrao et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

---

Correction to Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-I integrase inhibitors. *Retrovirology* 2009, **6**:25. Since the recent publication of our article (Neamati, *Retrovirology* 2009, **6**:25), we have noticed an error which we would like to correct and we would like to apologise to the readers for this mistake.

---

## Correction

The structure of BMS-707035 has not been publicly released. In Figure one on page 2 and a discussion on page 5 of our published paper [1], we mistakenly assigned a structure and activity data to BMS-707035. The structure and activity data that we mentioned actually belong to a different compound from the same group. The resistance pattern of BMS-707035 is "overlapping" rather than identical to raltegravir. Please see the following references [2,3] for a detailed description of their development of pyrimidine carboxamides.

## References

1. Serrao Erik, Odde Srinivas, Ramkumar Kavya, Neamati Nouri: **Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.** *Retrovirology* 2009, **6**:25.
2. Dicker IB, Samanta HK, Li Z, Hong Y, Tian Y, Banville J, Remillard RR, Walker MA, Langley DR, Krystal M: **Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.** *J Biol Chem* 2007, **282(43)**:31186-96.
3. Dicker IB, Terry B, Lin Z, Li Z, Bollini S, Samanta HK, Gali V, Walker MA, Krystal MR: **Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.** *J Biol Chem* 2008, **283(35)**:23599-609.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

